Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HCW9218 in Advanced Ovarian Cancer
NCT05145569Phase 2Withdrawn
- Start
- May 2024
- Primary completion
- May 2026
- Modality
- Fc-Fusion Proteins
01
Overview
Phase 2, randomised, open-label trial of HCW9218 in ovarian cancer (2 arms). Primary endpoints: Dose Limiting Toxicities at 8 weeks, Adverse Events Related to Treatment at 12 months and 2 more. Planned start May 2024; status: withdrawn.
02
Drugs
HCW9218
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT05145569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05145569.